BioMark’s Market Update Report
Vancouver, British Columbia – (February 4th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020. “BioMark is not aware of any negative news that has impacted its share price recently. We continue to execute […]
BIOMARK’S SCIENTIFIC ADVISOR NAMED DEAN OF SCHULICH SCHOOL OF MEDICINE AND DENTISTRY
Vancouver, British Columbia – (January 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020. Dr. Yoo has an international reputation as a pioneering […]
BIOMARK DIAGNOSTICS REVIEWS 2019 AND OUTLINES PLANS FOR 2020
Vancouver, British Columbia – (December 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide 2019 round up and our outlook for 2020. Below are key highlights. 2019 Round Up 2019 has been a transformative year for BioMark and we anticipate that 2020 would be another […]
BIOMARK CLOSES THE OVER-SUBSCRIBED PRIVATE PLACEMENT OFFERING
Vancouver, British Columbia – (December 16th, 2019) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of November 21st, 2019, it has closed the non-brokered private placement for gross proceeds of $669,347.00 wherein BioMark issued 2,231,157 units at a price […]
Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics
Vancouver, British Columbia – (December 11th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to […]
BIOMARK ANNOUNCES PRIVATE PLACEMENT
Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000. Each Unit is composed […]
BIOMARK Announces Private Placement
Press_Release_BIOMARK_ANNOUNCES_PRIVATE_PLACMENT_May_9th_2017 (PDF)
BioMark Signs Letter of Intent for Licensing Relationship for Clinical Validation and Development
Vancouver, British Columbia – (November 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has signed a Letter of Intent (LOI) with a Chinese company named GuangDong Longhu (Longhu) related to an anticipated licensing relationship. BioMark has been in discussions with Longhu and its management […]
NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK’S ASSAY
Vancouver, British Columbia – (August 27th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “This […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest […]
